Login/Create Account
The US government has accused Germany of paying too little for innovative medicines. Consequently, an investigation is being initiated to determine whether Germany's pricing practices constitute unfair trade practices. Chancellor Friedrich Merz has firmly rejected these accusations, emphasizing that German prices align with international standards.
The discussion about drug prices is not new, but it is gaining momentum as the US and Europe pursue different approaches to pricing and financing healthcare services. Merz has stated that Germany wants to continue promoting innovative products while also protecting the health systems of its citizens. The findings of the investigation could have significant implications for trade relations between the US and Germany.
The discussion about drug prices is not new, but it is gaining momentum as the US and Europe pursue different approaches to pricing and financing healthcare services. Merz has stated that Germany wants to continue promoting innovative products while also protecting the health systems of its citizens. The findings of the investigation could have significant implications for trade relations between the US and Germany.
